Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
Retrieved on:
Friday, March 4, 2022
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, EQUIP, Risk, Private Securities Litigation Reform Act, Harvard Medical School, Patient, Adult, HSCT, GVHD, Population, Asthma, Forward-looking statement, Vomiting, Disease, Itolizumab, IV, Safety, CR, FDA, Methylprednisolone, Degenerative disease, Alopecia areata, CD6, Nausea, ORR, SEC, Cancer, Rash, Trial of the century, EDGAR, Adolescence, Diarrhea, Jaundice, Mortality, Partnership, McMillan, Itch, Nasdaq, Incidence, Irritation, Skin discoloration, Feedback, Therapy, Pharmaceutical industry, Vaccine, Medicine, the EQUATOR Study, Equillium, THE EQUATOR STUDY, EQUILLIUM
The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.
Key Points:
- The initiation of this pivotal study marks a major milestone for Equillium to assess itolizumabs potential as a life-changing advancement for patients suffering from acute GVHD, said Bruce Steel, chief executive officer of Equillium.
- Our Phase 3 study is supported by the compelling results from our EQUATE study demonstrating rapid and durable complete responses in high-risk acute GVHD patients.
- Hematologists and transplantation specialists have highlighted their enthusiasm for itolizumab as a potential therapeutic option and we are optimistic for these patients as we launch the EQUATOR study.
- If successful in the EQUATOR study, itolizumab could result in the first approval of a novel therapeutic in the first-line treatment of acute GVHD, potentially transformative in the field.